Sai Life Sciences has filed the transcript of its earnings call for the audited financial results for the quarter and year ended March 31, 2026. The call was held on Friday, May 15, 2026, at 04:00 PM (IST) pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015. The transcript has been uploaded to the company's website.

The company previously announced its audited financial results for FY26, reporting a 29% year-on-year increase in revenue to ₹2,192 crore. Profitability metrics improved significantly, with Profit After Tax (PAT) rising 109% to ₹355 crore from ₹170 crore in FY25. For Q4FY26, revenue from operations stood at ₹602 crore, a 4% year-on-year increase, while PAT for the quarter grew 18% to ₹104 crore.

Financial Performance

The company delivered robust operational efficiency across both the quarter and the full year. EBITDA for FY26 grew 56% to ₹661 crore, with the EBITDA margin expanding to 30% from 25% in the prior year. PAT margin improved to 16% from 10% in FY25. At the quarterly level, Q4FY26 EBITDA rose 17% to ₹189 crore, with an EBITDA margin of 31% compared to 28% in Q4FY25. The company also incurred a capital expenditure (capex) of ₹633 crore during FY26.

The following table presents the key financial metrics for the quarter and full year:

*before exceptional items

Five-Year KPI Trend

The investor presentation highlighted a consistent multi-year growth trajectory across key financial and return metrics. The following table summarises the five-year KPI trend from FY22 to FY26:

Management Commentary

Commenting on the performance, Mr. Krishna Kanumuri, Managing Director and CEO, said, "FY26 was an important year for Sai Life Sciences as we continued to deepen our relationships with global pharma customers, expand our integrated CRDMO capabilities, and invest for the next phase of growth. While the operating environment remains dynamic, we believe the long-term fundamentals of innovation-led outsourcing and supply chain diversification continue to remain strong, and we are well positioned to participate meaningfully in this opportunity."

Mr. Siva Chittor, Chief Financial Officer, added, "FY26 reflected strong execution across the business, supported by healthy growth in both revenues and EBITDA. As we enter the next phase of expansion, we remain focused on disciplined capital allocation, operational resilience, and investments that are closely aligned with customer demand and long-term strategic opportunities."

Business Updates

The investor presentation highlighted deepening engagement with global large pharma customers across Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) segments. Dedicated R&D team models gained strong traction, with relationships expanding from early discovery to commercial manufacturing. The company received commercial supply qualification from two additional large pharma customers. Integrated CRO strategy with biotech and pharma customers continued to scale, with growing cross-sell opportunities with existing CDMO customers and increased traction for larger and more customized discovery programs.

On the technology front, the company established a High-Throughput Experimentation (HTE) platform at its Hyderabad R&D campus and is expanding capabilities in Peptides and Antibody-Drug Conjugates (ADCs). Sai Life Sciences is also advancing digital and AI-led productivity initiatives across scientific operations, focused on improving speed, efficiency, and problem-solving capabilities. On the sustainability front, the company's Bidar manufacturing sites (Unit IV and Unit VI) have become the first sites of an Indian CRDMO to operate on 100% renewable power.

Earnings Call

Sai Life Sciences conducted its earnings call on May 15, 2026, to discuss the financial and business performance of the quarter and full year. Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, the recording of the earnings call is now available on the company's website. Key details of the call are as follows:

Sai Life Sciences Limited, one of India's leading integrated contract research, development, and manufacturing organizations (CRDMOs), announced on May 11, 2026, that its Bidar campus now operates entirely on renewable power. The campus comprises Unit IV — the company's flagship API manufacturing facility — and Unit VI, its animal health API manufacturing facility. With this milestone, the Bidar site becomes the first facility within an Indian CRDMO to achieve 100% renewable electricity usage.

A Phased, Multi-Year Transition

The shift to full renewable power at the Bidar campus followed a structured, multi-year effort that progressively increased the share of renewable energy in the site's total consumption. The journey from partial to complete renewable power spanned over half a decade, reflecting a deliberate long-term approach to energy transition.

The progression of renewable energy adoption at the Bidar campus is outlined below:

How the 100% Target Is Met

The current energy mix at the Bidar site relies on two complementary mechanisms to ensure that the entire electricity consumption is backed by renewable sources:

• 97% of the site's electricity requirement is sourced directly from solar and wind power through Open Access renewable energy agreements.
• 3% is balanced through the procurement of International Renewable Energy Certificates (I-RECs).

The transition also combined long-term renewable power purchase agreements with direct investments in clean energy infrastructure, including a 2.7 MW wind project under a group captive model. In parallel, Sai Life Sciences implemented energy-efficiency initiatives through equipment upgrades, process optimization, and digital monitoring systems to improve operational performance and reduce overall energy demand.

Leadership Perspective

Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, commented on the achievement: "The medicines we help bring into the world serve patients for years, often decades. The infrastructure behind them should be built with the same horizon in mind. Decisions around energy and scale therefore have to anticipate a future where sustainability, resilience, and resource efficiency will increasingly define how global industry operates. This transition reflects that long-term view."

Broader Organisational Impact

The Bidar milestone is part of a wider sustainability effort across the organisation. The key outcomes at the organisational level are summarised below:

The Bidar milestone reflects Sai Life Sciences' broader approach to integrating scientific innovation, operational excellence, and long-term sustainability into the company's growth strategy. With operations across India, the UK, and the US, the company continues to advance its sustainability commitments alongside its core pharmaceutical services business.